




THERAPEUTICS & DIAGNOSTICS

UTU TTO
Technology & IP
Available for
Licensing

Diagnostic, Prognostic, Therapeutic and Patient Stratification Tools for Cancers


Therapeutics for the most common & fatal type of brain cancer

- The molecular mechanism of treatment resistance in glioblastoma now revealed as overexpression of PP2A inhibitor PME-1 (Kaur et al., Cancer Res, Epub 2016)
- Efficient therapy is accomplished by combining the blocking of **PME-1** and/or **HDAC4** with chemotherapy
- Significant evidence in a xenograft mouse model
 - WO2014009609A1;
 - WO2014033367A1;
 - WO2012175798A2



Prognostic gene variants in aggressive prostate cancer

- Genetic predisposition to aggressive PrCa in Caucasians now traced to two synergistic germline mutations (*ms submitted*)
- Dual carriers of the two **gene variants** have a high risk of developing clinically relevant prostate cancer (OR 23.4) and especially aggressive PrCa such as CRPC (OR 36.6).
- Provides a new tool for patient stratification and for improved personalized care with more informed therapeutic actions
 - Priority patent application FI20165432 (public 11/2017)






Immunostimulatory glycocluster compounds for immunotherapy of cancers

- Used in monotherapy or as adjuvants to stimulate immune response towards malignant cells
- Significantly suppressed the growth of melanoma in a xenograft mouse model
 - WO2012175813A1,
 - US9221861B2; FI20155997 (public 06/2017)

Lectin-nanoparticle based diagnostics of various cancers

- Markedly improved assay performance using cancer-derived glycoforms of **CA125**, **CA15-3**, **CEA** and **PSA**
- Excellent avidity and S/N achieved using Eu-doped lectin nanoparticles
- PCT/FI2016/050490 (public 01/2017); FI20165588 (public 02/2018)



Separation diagnostics for ovarian cancer (OvCa)/endometriosis

- CA125** and **MDK** - with **EMILIN1** - indicates endometriosis instead of gynaecological cancer
- PCT/FI2016/050417 (public 12/2016)

Stratification biomarkers for ovarian (OvCa) and triple negative breast cancers (TNBC)

- Biomarkers and algorithm for stratification of patients to treatment-responsive and -unresponsive groups
- Facilitates the development of alternative treatments while reducing ineffective, toxic and costly therapy
 - WO2016066797A2; WO2016066800A1

CONTACT INFORMATION

Piia von Lode, PhD
Innovation Manager
piia.vonlode@utu.fi

University of Turku
Innovation Services / UTU TTO
FI-20014 TURUN YLIOPISTO

utu.fi/tto